RNA interference is a powerful tool to study loss-of-gene function in leukemic cells. Still, in 19 order to identify effective novel treatment strategies to target and eradicate leukemic stem 20 cells (LSCs), it is critically important to study gene function in a well-controlled and time-21 dependent manner. We implemented a lentiviral Tet-regulated miR-E shRNA dual color 22 37 38 39 40
vector in our in vitro and in vivo human leukemia models. Thus, we were able to efficiently 23 introduce doxycycline-inducible and reversible gene repression and trace and isolate 24 transduced miR-E shRNA expressing cells over time. As proof of concept we focused on the 25 non-canonical PRC1.1 Polycomb complex, which we previously identified to be essential for 26 LSCs (1). Here, we show that inducible downmodulation of PCGF1 strongly impaired the 27 growth of primary MLL-AF9 cells. Next, a Tet-regulated miR-E PCGF1 human xenograft MLL-28 AF9 leukemia mouse model was established, which revealed that early knockdown of PCGF1 29 at the onset of leukemia development significantly reduced peripheral blood chimerism 30 levels and improved overall survival. In contrast, knockdown of PCGF1 when leukemia was 31 already firmly established in the bone marrow proved insufficient to enhance overall 32 survival. Despite these findings, FACS analysis of MLL-AF9/miR-E PCGF1/CD45 + /GFP + 33 populations suggested that particularly cells with inefficient PCGF1 knockdown contributed 34 to leukemogenesis. In conclusion, by building in vivo xenograft leukemia inducible RNAi 35 models, we show that timing of gene knockdown critically impacts on the efficacy of 36 leukemia treatment and that clonal drift still plays a major role in the escape of LSCs.
Introduction 41 Leukemogenesis is a multistep process in which genetic and epigenetic changes affect 42 normal growth and differentiation of hematopoietic stem and/or progenitor cells, which can 43 ultimately lead to full leukemic transformation (2) (3) (4) (5) . With current therapies the majority of 44 the blast population is readily eradicated, though the rare quiescent population of LSCs is 45 more difficult to target and the major cause of relapse of the disease (6) (7) (8) . In order to 46 eradicate these LSCs, a better understanding of the molecular mechanisms underlying 47 human leukemia development is needed. 48 Loss-of-function studies using RNA interference screens have shown to be very useful 49 in identifying signaling pathways that are required for the proliferation and survival of 50 leukemic cells (1, (9) (10) (11) . Lentiviral short hairpin RNA (shRNA) expression vectors enable 51 sustained and sequence-specific downregulation of a target mRNA (12). The usual setup of 52 these RNA interference screens involves the transduction of leukemic cells with shRNAs 53 resulting in quick downregulation of designated targets, after which phenotypes are 54 evaluated in vitro or in vivo upon transplantation in (xenograft) mouse models. This however 55 does not reflect the situation in the clinic at which leukemia patients are diagnosed and 56 treated at the full-blown stage. Therefore, in order to evaluate the role of target genes in the 57 maintenance and propagation of leukemic (stem) cells and to truly evaluate the efficacy of 58 novel treatment options, one needs to first establish a leukemia within the bone marrow 59 microenvironment and then perform gene-function studies. 60 The inducible Tet-regulated (Tet-On) shRNA expression system provides an attractive 61 approach to study genes required for leukemic transformation (initiation) as well as for 62 maintenance and survival (13) (14) (15) (16) . It allows controlled gene regulation by doxycycline 63 inducible and reversible gene repression to study direct consequences at any chosen time 64 point during disease progression. In addition, essential genes can be studied where 65 constitutive knockdown might be toxic. To introduce Tet-regulated shRNA expression 66 vectors in in vivo xenograft leukemia models would be very promising as a predictive model 67 for therapy in (leukemia) patients. Treatment strategies and potential relapse of disease can 68 be further studied upon discontinuing doxycycline treatment. Identifying and prospectively 69 isolating different AML subclones expressing Tet-regulated shRNAs using leukemia specific 70 plasma membrane markers can be used to study clone-specific dynamics in response to 71 shRNA-mediated knockdown (de Boer et al, in submission) . 72 In this study, we implemented a Tet-regulated miR-E shRNA expression vector, as The lentiviral miR-E expression vector pRRL.TRE3G.GFP.miRE.PGK.mCherry.IRES.rtTA3 84 (LT3GECIR) was generously provided by the Zuber lab (17). miR-E shRNAs were designed for 85 RING1B, PCGF1, KDM2B and a SCR control (see S1 Table) and generated as described by 86 Fellmann et al (17 demonstrated by >95% mCherry + /GFP + cells ( Fig 1A) . To test the efficiency of the 170 knockdown, qRT-PCR analysis was performed on K562 cells expressing miR-E RING1B, miR-E 171 PCGF1 or miR-E KDM2B in the presence or absence of doxycycline for 4 days (Fig 1B) . Next, 172 we examined the effect of dox withdrawal to verify that the knockdown was reversible (Fig   173   1C ). In the presence of dox, miR-E KDM2B cells became GFP-positive within two days, 174 coinciding with a 60% knockdown in KDM2B expression ( Fig 1C) . In order to evaluate the 175 reversibility of the system, cells were withdrawn from dox. Already after two days of dox 176 withdrawal the GFP percentage started to drop, but it took 10 days before all GFP expression 177 was completely gone. At that timepoint, KDM2B expression levels were also again up to 178 normal levels ( Fig 1C) . Thus, these lentiviral vectors provide an efficient dox-inducible and 179 reversible shRNA expression tool, which is useful to perform gene function studies in a time- to the mice in food pellets (625 ppm) either at the start or at 10 weeks after secondary 212 transplantation when leukemia was already established in the BM (Fig 3B) . Control mice that 213 did not receive any doxycycline, developed leukemia within 150 days ( Fig 3C) . Mice that 214 were treated with doxycycline from the start showed significant prolonged survival until the 215 end of the experiment (Fig 3C) . Peripheral blood chimerism levels (MLL-AF9/miR-E 216 PCGF1/CD45 + ) remained low over time ( Fig 3D) . To investigate if we could treat mice at a 217 later stage in the development of leukemia, we also started treatment of doxycycline 10 218 weeks after secondary transplantation when average blood chimerism levels were already 219 5%, a situation that would more faithfully mimic the patient situation ( Fig 3E) . While 220 chimerism levels increased over time in untreated mice after week 10, this increase was 221 clearly delayed in mice treated with doxycycline ( Fig 3E) . Nevertheless, leukemia did develop 222 in mice treated from week 10 and mice were sacrificed when peripheral blood chimerism 223 levels reached 30% and ultimately within this experiment no significant differences in overall 224 survival were reached ( Fig 3C, 3D and 3E) . 225 Even though substantial levels of ~65% chimerism (MLL-AF9/miR-E PCGF1/CD45 + ) were 226 observed in the BM of mice treated with doxycycline at week 10, these levels were still 227 significantly lower compared to control mice ( Fig 3F) . Intriguingly, FACS analysis of MLL-228 AF9/miR-E PCGF1 mCherry + /CD45 + populations in doxycycline-treated mice revealed strong 229 variation in GFP positivity (Fig 3F and S2B Fig) . We questioned whether in vivo all BM cells 230 would be equally sensitive to dox treatment as compared to in vitro conditions. To do so, a 231 mouse (#1) that had not been treated with dox and had developed leukemia was 232 administered with dox for 5 days before sacrifice. 82% of these cells were GFP positive and 233 while this was somewhat lower compared to the 95% that was reached in vitro, this was still 234 higher than percentages seen in mice that were treated with doxycycline for 8-14 weeks, 235 which showed average GFP levels of 63% ( Fig 3F) . These data suggest that there was some 236 selection for those clones that did not express GFP, or only at very low levels. Indeed, the 237 highest chimerism levels were seen in mice with the lowest percentage of GFP + cells. 238 Moreover, we sorted the bright, mid and negative GFP populations and analyzed the 239 efficiency of PCGF1 knockdown by qRT-PCR ( Fig 3G) . The GFP negative population showed 240 similar PCGF1 expression levels as the no doxycycline control group, PCGF1 knockdown was 241 more efficient in the GFP mid population and the highest knockdown was achieved in the 242 GFP bright population ( Fig 3G) . Thus, these data indeed indicate that it were particularly those In contrast, and somewhat unexpectedly, the survival of mice in which dox 295 treatment was initiated at week 10 was not significantly prolonged. We decided to start the 296 treatment of mice when peripheral blood chimerism levels had reached about 5%, which in 297 our view would be a moment that would faithfully recapitulate the situation when patients 298 would enter the clinic. These data strongly contrast our in vitro data in which we observed 299 that PCGF1 knockdown strongly impaired MLL-AF9 cell growth, and also the effects seen in 300 vivo when mice were treated directly after transplantation, which were very promising. 301 However, once leukemia was established in the BM niche the effects were minor, which 302 would have major implications for the efficacy of PCGF1 inhibition as a treatment modality. 303 We also observed that doxycycline treated mice with low chimerism levels in the blood, still 304 had substantial levels of engraftment in the BM, suggesting that the niche would provide 305 protective factors that counteract loss of PCGF1. Clearly, the bone marrow 306 microenvironment might play a protective role in the survival of leukemic cells (37-39). 307 Indeed, we observed that MLL-AF9 cells cultured in the presence of murine MS5 
